Complex temporal changes in TGFβ oncogenic signaling drive thyroid carcinogenesis in a mouse model

Dong Wook Kim, Robert L. Walker, and Sheue-yann Cheng*

Introduction

Thyroid cancers constitute the most frequent endocrine neoplasia. The incidence rate of thyroid cancer has been rising sharply since the mid-1990s, and it is the fastest increasing cancer in both men and women (1). The majority of thyroid cancers are differentiated thyroid cancers with papillary and follicular types (2). The incidence of thyroid cancer has been rising sharply since the mid-1990s, and it is the fastest increasing cancer in both men and women (1). The majority of thyroid cancers are differentiated thyroid cancers with papillary and follicular types (2).

Despite recent advances, understanding of molecular genetic alterations underlying thyroid carcinogenesis remains unclear. One key question is how dynamic temporal changes in genomic expression affect carcinogenesis as the disease progresses. To address this question, we used a mouse model that spontaneously develops follicular thyroid cancer similar to human cancer (ThrbPV/PV mice). Using complementary DNA microarrays, we compared global gene expression profiles of thyroid tumors of ThrbPV/PV mice with the age- and gender-matched thyroid tumors of wild-type mice at 3 weeks and at 2, 4, 6, and 14 months. These time points covered the pathological progression from early hyperplasia to capsular invasion, vascular invasion and eventual metastasis. Microarray data indicated that 462 genes were upregulated (Up-cluster genes) and 110 genes were downregulated (Down-cluster genes). Three major expression patterns (trending up, cyclical and spiking up and then down) and two (trending down and cyclical) were apparent in the Up-cluster and Down-cluster genes, respectively. Functional clustering of tumor-related genes followed by Ingenuity Pathways Analysis identified the transforming growth factor β (TGFβ)-mediated network as key signaling pathways. Further functional analyses showed sustained activation of TGFβ receptor–pSMAD2/3 signaling, leading to decreased expression of E-cadherin and increased expression of fibronectin, vimentin, collagens and laminins. These TGFβ-induced changes facilitated epithelial-to-mesenchymal transition (EMT), which promotes cancer invasion and migration. Thus, complex temporal changes in gene expression patterns drive thyroid cancer progression, and persistent activation of TGFβ–TGFβRII–pSMAD2/3 signaling leads to EMT, thus promoting metastasis. This study provides new understanding of progression and metastatic spread of human thyroid cancer.

Abbreviations: EMT, epithelial-to-mesenchymal transition; FTC, follicular thyroid cancer; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; IPA, Ingenuity Pathways Analysis; RT–PCR, reverse transcription–PCR; TGF, transforming growth factor; TGFβRs, TGFβ receptors; WT, wild type.

Materials and methods

Mouse strains

The animal studies were carried out according to the protocol approved by the National Cancer Institute Animal Care and Use Committee. Mice harboring the ThrbPV gene (ThrbPV/PV mice) were generated and genotyped as described earlier (4). Littermates with a similar genetic background were used as a control in experiments.

Microarray analysis

The mouse arrays contained 20 000 complementary DNAs. Hybridization, scanning and image analysis were performed as described previously (www.ncbi.nlm.nih.gov/geo/). Briefly, fluorescent-labeled complementary DNA was synthesized from ~20 μg of pooled RNA of five mice by oligo(T)-primed polymerization in the presence of aminoalyl-deoxycytidine triphosphate (Amersham Pharmacia Biotech, Piscataway, NJ) and coupled with either Cy-3 or Cy-5. Image analyses were performed using DeArray software (Signal Analytics, Vienna, VA) (15). The two fluorescent images (red and green channels) obtained from one array constitute the raw data used to calculate differential gene expression ratio values. The ratios of the red intensity to the green intensity (R/G) for all targets were determined, and the data were stored in a FileMaker Pro database (FileMaker, Santa Clara, CA).

RNA extraction and real-time PCR

Thyroid lobes from wild-type (WT) and ThrbPV/PV mice were homogenized in TRIzol (Invitrogen, CA) (13–15). Briefly, fluorescent-labeled complementary DNA was synthesized from ~20 μg of pooled RNA of five mice by oligo(T)-primed polymerization in the presence of aminoalyl-deoxycytidine triphosphate (Amersham Pharmacia Biotech, Piscataway, NJ) and coupled with either Cy-3 or Cy-5. Image analyses were performed using DeArray software (Signal Analytics, Vienna, VA) (15). The two fluorescent images (red and green channels) obtained from one array constitute the raw data used to calculate differential gene expression ratio values. The ratios of the red intensity to the green intensity (R/G) for all targets were determined, and the data were stored in a FileMaker Pro database (FileMaker, Santa Clara, CA).

Western blot analysis

Thyroid tissues preparation from WT and ThrbPV/PV mice and western analysis were carried out as described previously (12). The antibodies were total...
anti-SMAD2 (1:100 dilution, #5678, Cell Signaling, MA), anti-GAPDH (1:100 dilution, #2118, Cell Signaling, MA), anti-TIMP3 (1:100 dilution, #5673, Cell Signaling, MA), anti-TGBFRII (1:1000 dilution, #3713, Cell Signaling, MA), anti-TGFBI (1:300 dilution, 10188-1-AP, Proteintech, IL), anti-vimentin (1:1000 dilution, #5741, Cell Signaling, MA), anti-E-cadherin (1:1000 dilution, #4605, Cell Signaling, MA), anti-fibronectin (1:250 dilution, ac-6952, Santa Cruz, CA), anti-LAMC1 (1000: sc-5584, Santa Cruz, CA), anti-PSMA2/3 (1:1000 dilution, sc-11769, Santa Cruz, CA) and anti-collagen type IV (1:200 dilution, AB-769, Millipore, MA).

Immunohistochemical staining

Immunohistochemical staining was performed as described previously (17). Antibodies were TGBFRII (1:100 dilution, #3713, Cell Signaling, MA), pSMAD2/3 (1:1000 dilution, sc-11769, Santa Cruz, CA) and Ki-67 (1:50 dilution, Thermo Scientific, NJ).

Determination of serum TGFβ1

The serum levels of TGFβ1 were determined using a TGF beta1 Mouse ELISA kit (ab119557, Abcam, MA) according to the manufacturer’s instructions.

Confocal fluorescence microscopy

Primary cultured thyroid cells were obtained from WT and Thrb<sup>PV/PV</sup> mice as described previously (7). Cells (4 × 10<sup>4</sup> cells/well) were seeded in a chambered coverglass (Thermo Scientific, NY, #155411) and were cultured in Coon’s modified Ham’s F-12 medium supplemented with 5% bovine serum containing 10 μg/ml insulin, 0.4 ng/ml cortisol, 5 μg/ml transferrin, 10 ng/ml glycyrrhetinic acid, 10 ng/ml somatomedin and 1 milliunit/ml thyroid-stimulating hormone (Sigma) for 24 h. Then the cells were treated with or without TGFβ1 (10 ng/ml) (Cell Signaling, MA, #8915) for 48 h. All subsequent steps were carried as described previously (17). Antibodies were anti-vimentin (1: 100 dilution, #5741, Cell Signaling, MA), anti-FN1 (1:400 dilution, ab6328, Abcam, MA), anti-TFF1 (1:100, sc-13040, Santa Cruz, CA) and anti-PAX8 (1:1000 dilution, 10356-1-AP, Proteintech, IL) for 1 h.

Wound healing assay

Primary cultured thyroid cells obtained from WT and Thrb<sup>PV/PV</sup> mice were seeded in a 12-well plate in culture media as described above. After 24 h, cells were wounded with a p200 tip and washed with 1× PBS, and then media was replaced with culture media supplemented with 2% bovine serum with or without TGFβ1 (10 ng/ml). Pictures were taken at time point 0, 24 and 48 h after TGFβ1 treatment. The distance between cells was measured using ImageJ software (NIH).

Statistical analysis

Data are expressed as mean ± standard error of the mean. Significant differences between groups were calculated using Student’s t-test via GraphPad Prism 5 (GraphPad Software, San Diego, CA). P < 0.05 was considered statistically significant.

Results

Complex temporal changes in gene expression patterns during thyroid carcinogenesis

To ascertain the changes in global gene expression during thyroid cancer progression, we analyzed the microarray data obtained from comparison of thyroid tumors of male Thrb<sup>PV/PV</sup> mice with the age- and gender-matched thyroid of WT mice (n = 3 for each genotype) at the ages of 3 weeks and at 2, 4, 6 and 14 months. These time points covered the pathological progression from early hyperplasia beginning at 3 weeks to capsular and vascular invasion occurring at 5–6 months and to metastasis detectable at 8–9 months and onward (6). A total of 572 genes with expression ratios >2 were selected for further analysis (Figure 1A). Two major gene clusters, termed Up-cluster and Down-cluster, of altered gene expression profiles were apparent during thyroid carcinogenesis of Thrb<sup>PV/PV</sup> mice. Four hundred and sixty-two genes remained mostly upregulated in the Up-cluster and 110 genes remain mostly downregulated in the Down-cluster. The extent of changes was reflected in the intensities of the heat bar shown in Figure 1A. The complete list of 572 genes with fold of changes in a time-dependent manner is shown in Supplementary Table A, available at Carcinogenesis Online.

Further analyses of the gene expression profiles in the two clusters revealed major patterns of changes during thyroid carcinogenesis from 3 weeks of age up to 14 months. Three major patterns were identified from the Up-cluster (Figure 1B-a) and two from the Down-cluster (Figure 1C-a). As shown in Figure 1B-a, for the Up-cluster the most frequent pattern of gene expression was ‘trending up’ (65%; Type I). Two genes representative of this pattern of expression, fibronectin (Fn1) and TGFβ induced (Tgbhi), are shown in Figure 1B-b. Less frequent were the ‘cyclical’ pattern (21%; Type II) and the ‘spiking up and then down’ pattern (14%; Type III). Two representative genes with the ‘cyclical’ pattern are glycine amidinotransferase (Gatm) and pleiotrophin (Ptn) (Figure 1B-c). The aminolevulinic acid synthase 2 (Alas2) and the presynaptic cytomatrix protein (Piccolo) genes exhibited the pattern of spiking up at 8 weeks, and then decreasing (Figure 1B-d). For the Down-cluster genes, 75% displayed the ‘trending up’ pattern (Figure 1C-a). As shown in Figure 1C-b, the tumor-associated calcium signal transducer (Tacstd2) and the SPARC-like 1 (Sparc1) genes are two representative examples of this pattern. Only 25% of the genes displayed the ‘cyclical’ pattern of expression (Figure 1C-a).

Two representative genes with this pattern are annexin A5 (Anxa5) and TIMP metalloproteinase inhibitor (Timp3) (Figure 1C-c). These data indicate that complex alterations in the expression of genes in a temporal-dependent manner drive the progression of thyroid cancer from hyperplasia to tumor invasion and metastasis.

Identification of activated TGFβ signaling network in thyroid carcinogenesis of Thrb<sup>PV/PV</sup> mice

Functional clustering analysis of the 572 genes showed that genes with altered expression functioned as key regulators in cell death/survival, cell proliferation/growth and cell development (22% for each category) and in cellular movement and morphology (17% for each category). To elucidate oncogenic genes that undergo temporal alterations in expression, which contribute to thyroid carcinogenesis, we used Ingenuity Pathways Analysis (IPA) to search for genes known to be involved in cancer development. Among those genes identified by IPA, we found 23 in the Up-cluster and 15 in the Down-cluster, which play key roles (Table I). These genes exhibited different temporal patterns (Types I and II in the Up-cluster and Types I and II in the Down-cluster) and were involved in a wide range of critical cellular functions such as proliferation, apoptosis, invasion, metastasis and migration (Table I). Among these genes, serpin peptidase inhibitor, clade F, member 1, (Serpinf1) (18), Fn1 (19), vimentin (Vim) (19,20), pericentriolar material 1 (Pcm1) (21), the prolactin receptor (Prlr) (22) and Timp3 (23) are reported to be involved in human thyroid cancer.

The data reported thus far suggest complex networks of genes undergo temporal changes as thyroid cancer progresses. We therefore used IPA to further ascertain how the genes in Table I could be interconnected to drive thyroid carcinogenesis. IPA identified four potential networks with top functions involved in cancer/cell movement/cardiomyocyte system (network 1), cancer/connnective tissue disorder/inflammatory diseases (network 2), connective tissue disorder/embryonic development (network 3) and cell movement/tissue development/cellular growth (network 4). IPA-computed scores of 31, 25, 11 and 10 for networks 1, 2, 3 and 4, respectively, indicate a >95% confidence that these results were not by random chance.

Further analysis showed that among the 35 regulators predicted by IPA to be involved in network 1, 14 were identified in our analysis as shown in Table I (40% of total 38 genes listed in Table I). In Figure 2A, these 14 genes are marked by solid black (as opposed to open) symbols. However, a lower number of genes, 12, 6 and 6 genes listed in Table I were found to participate in the activities of networks 2, 3 and 4, respectively.

Therefore, we focused our in-depth analysis on the role of network 1 in thyroid carcinogenesis.

Central to network 1 is the signaling pathway mediated by the TGFβ (Figure 2A). TGFβ is a key player in cell proliferation, differentiation and apoptosis, and its aberrant signaling is associated with cancer development (24). Among the genes listed in Table I, 14 genes in the Up-cluster (Tgbhi, Anxa1, Fn1, Lph, Ltf, Igf1, Vim, Lame1, Col4a1, Nrr2f, Ucp2, Bgn, Tgfr and Col3a1) and seven genes in the Down-cluster (Agr2, Nkbia, Lmo7, Timp3, Tacstd2, Timp4 and Fasn) are affected directly or indirectly by TGFβ signaling (25–44).
We therefore used qRT–PCR to validate the time-dependent gene expression profiles obtained by array analysis. Examples of genes used for validation are shown in Figure 2B. Consistent with array data, qRT–PCR shows that the expression of the TGFβ-induced, 68 kDa (Tgfbi), exhibited the pattern of 'trending up' (Up-cluster, Type I) (Figure 2B-a). Similarly, the expression pattern of Fn1 and laminin γ 1 as determined by qRT–PCR was in line with that determined by arrays (Figure 2B-b and -c, respectively). Figure 2B-d shows the expression pattern of the Timp3 gene shown by qRT–PCR was consistent with that found by microarray data (Figure 1C-c) (Down-cluster; Type II). In addition, examination of other genes involved in TGFβ signaling shows that the expression patterns of TgfbrII (Figure 2B-e) and Vim (Figure 2B-g) were consistent with those of microarray data, but expression level of E-cadherin determined by qRT/PCR was lower than that determined by microarray analysis (Figure 2B-f).

In tumors, TGFβ acts as either a tumor suppressor or a proto-oncogene, depending on cell context and tumor stage (45). Cancer cells often evade the growth inhibitory effects of TGFβ but retain the TGFβ-mediated cellular functions that promote tumor progression. Accordingly, we next sought to elucidate how TGFβ signaling could affect thyroid carcinogenesis of ThrbPV/PV mice. The TGFβ canonical signaling is via the TGFβ receptors (TGFβRs)–SMAD pathways. Upon binding to TGFβ, TGFβRs dimerize and phosphorylate intracellular SMAD proteins. Phosphorylated SMAD (pSMAD) proteins translocate into the nucleus to regulate TGFβ-dependent target genes. Our western blot analysis (Figure 3A) showed that TGFβRII protein abundance was markedly higher (lanes 7–12) in ThrbPV/PV mice than in WT mice (lanes 1–6) at all ages; and moreover, this abundance increased as mice aged (Figure 3A-a). The increased abundance of TGFβRII protein was accompanied by a concomitant age-dependent increase of pSMAD2/3 (Figure 3A-b). However, there was no apparent difference between WT and ThrbPV/PV mice in protein abundance of total SMAD2/3 (compare Figure 3A-b, lanes 7–12 to 1–6). Panel d shows the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) loading control.

Immunohistochemical analysis also revealed increased expression of TGFβRII protein in the thyroid lesions. Figure 3B-I shows intense staining of TGFβRII protein in the hyperplastic follicular cells of ThrbPV/PV mice (panel b) but not in the normal follicular cells.
Table 1. Genes associated with tumor development

<table>
<thead>
<tr>
<th>Gene</th>
<th>Gene name</th>
<th>Maximal fold changes</th>
<th>Type</th>
<th>Proliferation</th>
<th>Apoptosis</th>
<th>Invasion</th>
<th>Metastasis</th>
<th>Migration</th>
<th>Thyroid cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Up-cluster</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lcn2</td>
<td>Lipocalin 2</td>
<td>55.02</td>
<td>I</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>Tgfb1</td>
<td>Transforming growth factor, beta-induced, 68kDa</td>
<td>22.5</td>
<td>I</td>
<td>*</td>
<td></td>
<td></td>
<td>*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serpinf1</td>
<td>Serpin peptidase inhibitor, clade F, member 1</td>
<td>9.33</td>
<td>I</td>
<td>*</td>
<td></td>
<td></td>
<td>*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anxa1</td>
<td>Annexin A1</td>
<td>9.21</td>
<td>I</td>
<td>*</td>
<td>*</td>
<td></td>
<td>*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fln1</td>
<td>Fibronectin 1</td>
<td>8.05</td>
<td>I</td>
<td>*</td>
<td></td>
<td>*</td>
<td>*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lbp</td>
<td>Lipopolysaccharide binding protein</td>
<td>7.84</td>
<td>I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ltf</td>
<td>Lactotransferrin</td>
<td>5.95</td>
<td>I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Camk1d</td>
<td>Calcium/calmodulin-dependent protein kinase ID</td>
<td>4.41</td>
<td>I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Igf1</td>
<td>Insulin-like growth factor</td>
<td>4.16</td>
<td>II</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smarc1</td>
<td>SWI/SNF-related matrix-associated actin-dependent regulator chromatin, subfamily b, member 1</td>
<td>4.26</td>
<td>II</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vim</td>
<td>Vimentin</td>
<td>3.99</td>
<td>I</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Col18a1</td>
<td>Collagen, type XVIII, alpha 1</td>
<td>3.82</td>
<td>II</td>
<td></td>
<td>*</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grn</td>
<td>Granulin</td>
<td>3.7</td>
<td>I</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lamc1</td>
<td>Laminin, gamma 1</td>
<td>3.67</td>
<td>I</td>
<td></td>
<td>*</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Col4a1</td>
<td>Collagen, type IV, alpha 1</td>
<td>3.61</td>
<td>II</td>
<td></td>
<td>*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ehf</td>
<td>Ets homologous factor</td>
<td>3.6</td>
<td>II</td>
<td></td>
<td>*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tnms</td>
<td>Thymidylate synthetase</td>
<td>3.56</td>
<td>II</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ns2f2</td>
<td>Nuclear receptor subfamily group F, member 2</td>
<td>3.53</td>
<td>I</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ucp2</td>
<td>Uncoupling protein 2</td>
<td>3.38</td>
<td>I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bgn</td>
<td>Biglycan</td>
<td>3.2</td>
<td>II</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tfrc</td>
<td>Transferrin receptor</td>
<td>3.1</td>
<td>II</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Col3a1</td>
<td>Collagen, type III, alpha 1</td>
<td>3.1</td>
<td>II</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ptn</td>
<td>Pleiotrophin</td>
<td>3.0</td>
<td>II</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Down-cluster</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Agr2</td>
<td>Anterior gradient 2 homolog</td>
<td>0.5</td>
<td>I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Esr1</td>
<td>Estrogen receptor 1</td>
<td>0.5</td>
<td>II</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smo</td>
<td>Smoothened frizzled family receptor</td>
<td>0.49</td>
<td>I</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pcm1</td>
<td>Pericentriolar material 1</td>
<td>0.49</td>
<td>I</td>
<td>*</td>
<td></td>
<td></td>
<td>*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gnas</td>
<td>GNAS (guanine nucleotide binding protein, alpha stimulating) complex locus</td>
<td>0.48</td>
<td>I</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flr2</td>
<td>Fibronectin leucine rich transmembrane protein 2</td>
<td>0.47</td>
<td>I</td>
<td></td>
<td>*</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anxa5</td>
<td>Annexin A5</td>
<td>0.46</td>
<td>II</td>
<td></td>
<td></td>
<td>*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nfkbia</td>
<td>Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha</td>
<td>0.45</td>
<td>I</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prlr</td>
<td>Prolactin receptor</td>
<td>0.38</td>
<td>I</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lmo7</td>
<td>LIM domain 7</td>
<td>0.38</td>
<td>I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Timp3</td>
<td>TIMP metalloproteinase inhibitor 3</td>
<td>0.34</td>
<td>II</td>
<td>*</td>
<td></td>
<td>*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tacstd2</td>
<td>Tumor-associated calcium signal transducer 2</td>
<td>0.32</td>
<td>I</td>
<td></td>
<td></td>
<td>*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Timp4</td>
<td>TIMP metalloproteinase inhibitor 4</td>
<td>0.31</td>
<td>II</td>
<td>*</td>
<td></td>
<td>*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fasn</td>
<td>Fatty acid synthase</td>
<td>0.31</td>
<td>I</td>
<td>*</td>
<td></td>
<td>*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Txnip</td>
<td>Thioredoxin interacting protein</td>
<td>0.29</td>
<td>I</td>
<td></td>
<td></td>
<td>*</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Maximal fold changes (bold values): the ratio of highest value versus lowest value at five selective time points in mice aged from 3 weeks to 14 months.
Progressive oncogenic signaling in thyroid carcinogenesis

Fig. 2. (A) Predicted signaling network of genes associated with tumor development in Thrb<sup>PV/PV</sup> mice. Genes related to tumor development listed in Table I were assessed by IPA. Solid black (filled) symbols indicate the genes identified from arrays and shown in Table I. The functional category of each gene is denoted by either open or filled symbols. The functional relationship among genes is shown with a solid line to indicate binding only or a broken line to indicate indirect interaction, and with arrowheads attached to indicate acts on. (B) Validation of the extent of gene expression from arrays by quantitative real-time PCR. Total RNA was extracted from thyroids of WT and Thrb<sup>PV/PV</sup> mice at the indicated age, as described in Materials and methods. Seven representative genes were selected for gene validation. Three of them were from the Up-cluster (a–e), one from the Down-cluster (d) and three (e–g) were genes related with TGFβ signaling: (a) Tgfbi, (b) Fn1, (c) Lamc1, (d) Timp3, (e) TgfbrII, (f) E-cadheirn and (g) Vim. Open bars indicate microarray data; filled bars indicate data from quantitative real-time PCR.
of WT mice (panel a). The staining shown in panel b was specific because very little background signaling was detected when no primary antibodies were used in either the normal follicular cells (panel e) or the tumor cells (panel f). A count of the cells stained positively with TGFBRII showed ~3-fold more hyperplastic cells in Thrb<sup>PV/PV</sup> mice than normal cells in WT mice (Figure 3B-II-a). Consistent with this observation, Figure 3B-I shows more tumor cells of Thrb<sup>PV/PV</sup> mice (panel d) than normal cells of WT mice (panel c) when intensely
stained with anti-pSMAD2/3. As indicated in the counting of positively stained cells (Figure 3B-II-b), ~3-fold higher percentage of cells stained with pSMAD2/3 was detected in thyroids of ThrbPV/PV mice than in WT mice. These data indicate an activated TGFβ signaling during thyroid carcinogenesis of ThrbPV/PV mice. It is known that activation of TGFβ signaling leads to increased cell proliferation at various cancers (46–48). We therefore further stained the thyroids with nuclear proliferation marker, Ki-67. Panel h (Figure 3B-I) shows that tumor cells were intensively stained with anti-Ki-67 antibodies than in the normal follicular cells of WT mice (panel g). The Ki-67-positive cells were counted and the quantitative data are shown in Figure 3B-II-c, indicating ~7.5-fold increase in the Ki-67 stained cells in thyroids of ThrbPV/PV mice.

We further assessed whether serum TGFβ1 levels of ThrbPV/PV mice were elevated to stimulate TGFBRII–SMAD signaling. Indeed, Figure 3C shows that at 3–4 months of age, serum TGFβ1 levels in ThrbPV/PV mice were significantly higher than those in WT mice (compare data group 2 with data group 1). TGFβ1 serum levels of ThrbPV/PV and WT mice were further increased at age 5–7 months. Although the TGFβ1 serum level of ThrbPV/PV mice was not significantly different

![Image of Figure 3](https://academic.oup.com/carcin/article-abstract/34/10/2389/2463726)
from that of WT mice at age 5–7 months (data groups 3 and 4), the TGFβ1 serum level of ThrbPV/PV mice tended to be higher (data group 3 versus 4). No additional increases in TGFβ1 serum levels were detected in mice aged 10–12 months. These data indicate that in addition to the elevated protein abundance of TGFBRII, increased serum TGFβ1 levels also contributed to the activation of TGFBRII–SMAD signaling. Other evidence of TGFB–TGFBRII–SMAD signaling activation was the increased expression of its downstream target gene Tgfbi (Up-cluster, Table I) at the messenger RNA level (Figure 1B-b) and at the protein level shown in Figure 3D-a. Likewise, the expression of the Timp3 gene (Down-cluster; Table I, Type II), which is negatively regulated by the TGFB–TGFBRII–SMAD pathway, was also reduced at the messenger RNA level (Figure 1C-c) and at the protein level (Figure 3D-b). Taken together, these data indicate that TGFB–TGFBRII–SMAD signaling was activated to promote thyroid carcinogenesis of ThrbPV/PV mice.

Fig. 4. TGFβ1 induces EMT in thyroid tumors of ThrbPV/PV mice. (A) Primary cultured thyroid cells were plated in a chamber slide, and cells were cultured for 48 h before immunostaining. The purity of the isolated thyroid cells from WT mice (A-I) and tumor cells (A-II) was determined using antibodies for thyroid-specific markers: anti-TTF1 (A-I and A-II, a and b) and anti-PAX8 (A-I and A-II, c and d). More than 95% of cells showed positive staining of thyroid-specific markers. (B). Increased EMT activities by TGFβ1 treatment in ThrbPV/PV mice. Antibodies for vimentin (B-I) and FN1 (B-II) were used to examine the EMT progression in primary cultured cells obtained from WT and ThrbPV/PV mice. Primary cultured thyroid cells were treated with (B-I, and B-II, c, d, g and h) or without (B-I, and B-II, a, b, e and f) TGFβ1 for 48 h, as described in Materials and methods.
Progressive oncogenic signaling in thyroid carcinogenesis

Induction of EMT by activated TGFβ signaling to increase invasion and metastasis

In advanced cancers, it is known that TGFβ elicits EMT by advanced transcriptional and posttranscriptional regulation of key regulators that affect cell adhesion, cell mobility and migration (49). As shown in Table I and Figure 2A, several genes regulated by TGFβ signaling were involved in cell adhesion and migration, such as Fln1 (50), Vim (51), Col18a1 (52), Lams1 (53), Col4a1 (54), Col3a1 (55), Timp3 (23) and Timp4 (56). Such gene expression profiles raised the question of whether activated TGFβ signaling in the thyroid of TbrbPV/PV mice could lead to induction of EMT to increase cell invasion and metastasis. To test this possibility, we determined the protein abundance of E-cadherin because its repressed expression is the hallmark of EMT (57). Indeed, Figure 3E-a shows that the protein abundance of E-cadherin in thyroids of TbrbPV mice (lanes 7–12) was very low at all ages compared with WT mice (lanes 1–6). Moreover, several mesenchymal proteins such as fibronectin (Figure 3E, panel b), vimentin (Figure 3E-c), laminin (Figure 3E-d) and collagen (Figure 3E-e) were elevated during cancer progression. These expressed protein data support the notion that activated TGFβ signaling led to EMT.

We carried out immunochemical analysis to examine directly whether TGFβ stimulation led to expression of its target genes critical for EMT, such as the Vim and Fln1 genes. We isolated primary tumor cells from thyroids of TbrbPV/PV mice and treated the cells with or without TGFβ1. Figure 4A-I and -II show that the normal thyrocytes and tumor cells isolated from thyroids of WT and TbrbPV mice, respectively, were indeed from follicular origins as the cells expressed the follicular cell transcription factor, TTF1, shown in panel a and panel b (co-stained with nuclear Hoechst dye). Panels c and d (Figure 4A-I and -II for normal thyrocytes from WT mice and tumor cells from TbrbPV mice, respectively) show that another follicular transcription factor PAX8 was also similarly expressed in the normal and tumor cells (Figure 4A-I and -II, respectively). The signals detected in panels a and b for TTF1 and panels c and d were specific because when no primary antibodies were used, no signals were detected as shown in the negative controls (panels e and f). At basal state (without treatment of TGFβ1), no vimentin-stained cells were observed in follicular cells from WT mice (Figure 4B-I, panels a and b). In the presence of TGFβ1, only a few normal follicular cells were stained with anti-vimentin antibodies (panels c and d). In contrast, in tumor cells isolated from thyroids of TbrbPV/PV mice, even without TGFβ1 treatment, more vimentin-stained cells (panel e) were clearly visible than those in normal follicular cells (compare panels a and c with panel e). Upon stimulation by TGFβ1, dramatically increased vimentin abundance was detected in thyroid tumor cells of TbrbPV/PV mice (panels g and h). We also similarly evaluated another mesenchymal target, fibronectin. We found visible staining against fibronectin antibodies in the thyroid tumor cells in the absence of TGFβ1 (Figure 4B-II, panel c), but not in the normal follicular cells of WT mice (Figure 4B-II, panel a). In the presence of TGFβ1, a marked increase in fibronectin protein abundance in thyroid tumor cells was observed in TbrbPV mice (Figure 4B-II, panel g) compared with normal follicular cells of WT mice (Figure 4B-II, panel c). These results provided direct evidence to indicate that TGFβ-mediated signaling led to increased expression of genes critical for EMT to promote invasion and metastasis of thyroid tumor cells.

Using wound-healing assays, we further carried out functional analysis by evaluating migration activity of primary tumor cells from TbrbPV/PV mice treated with or without TGFβ1 (Figure 5). As shown in Figure 5A, normal follicular cells from WT mice exhibited very slow movement without (panels a, b and c) or with TGFβ1 (panels d, e and f). In contrast, thyroid tumor cells from TbrbPV/PV mice showed a higher migration activity than that of normal follicular cells (compare panels g, h and i with panels a, b, c). A marked increase in cell migration activity of thyroid tumor cells was clearly evident upon stimulation by TGFβ1 (panels j, k and l). The migration distance of cells was measured. The quantitative data (Figure 5B) show that tumor cells exhibit a stronger migration activity than the normal follicular cells and that TGFβ1 further stimulates the migration activity of tumor cells by ~2- to 3-fold. Taken together, these results indicate that activated TGFβ signaling promotes thyroid carcinogenesis by increasing cell migration activity and EMT.
Discussion

The molecular genetic changes identified in patients frequently represent a snapshot of the disease at the time of diagnosis and analysis in an individual patient. More difficult to know are the detailed molecular genetic alterations leading to cancer at the time of diagnosis and what deleterious changes could be continuously occurring in patients if cancer is not diagnosed and treated. Our studies addressed these important questions by using ThrbPV/PV mice because it would be difficult to assess in patients. ThrbPV/PV mice spontaneously develop FTC, thereby allowing us to identify global alterations of gene expression patterns during cancer progression from onset of disease to the stage when death occurred. We found dynamic temporal changes in gene expression with major patterns of ‘trending up’, ‘cyclical’ and ‘spiking up and then down’ for the upregulated genes and ‘trending down’ and ‘cyclical’ patterns for the downregulated genes during cancer progression. These results indicate that dynamic temporal changes in gene expression are occurring via complex regulation. Therefore, analysis of the expression of the same genes in patients with the same type of cancer, but at different disease stages, could yield different results. These findings could explain the variable results from analyses of identical genes from different groups of patients at different disease stages (58).

Our analysis of tumor-related genes with altered expression (Table 1) uncovered an activated TGFβ-mediated network. Persistently elevated TGFβRII and its downstream effector, pSMAD2/3, were detected in the thyroid of ThrbPV/PV mice aged 3 to 10–12 months, indicative of sustained signaling via the network to drive tumor progression. We found elevated TGFβRII protein during thyroid carcinogenesis of ThrbPV/PV mice. However, the precise mechanism, leading to the increased TGFβRII protein, was not clear. In cancers, TGFβ acts to promote cancer progression by inducing EMT (49). Indeed, we found genes with reported functions in EMT were closely associated with an activated TGFβ-mediated network (Figure 2A and Table 1). Loss of expression of E-cadherin, a hallmark of EMT (57), was clearly evident during cancer progression (Figure 3E). Several mesenchymal protein-encoding genes such as laminins and collagen were persistently overexpressed during cancer progression (Table 1) (59–64). Other genes that have been shown to regulate EMT, such as fibronectin, vimentin, collagens, lipocalin, insulin-like growth factor 1, annexin A, calcium/calmodulin-dependent insulin-like growth factor 1 and pleiotrophin, were highly expressed (Table 1) (26,61,62,65–69).

The altered expression patterns of these genes would promote the loss of cell–cell adhesion and facilitate cell motility and invasion. Indeed, we showed that TGFβ stimulated the migration of primary tumor cells isolated from ThrbPV/PV mice. Thus, sustained activation of TGFβ-mediated signaling via the network promotes EMT to increase metastasis of thyroid tumor cells in ThrbPV/PV mice.

EMT is a multiple step process involving reorganization of cellular matrix components and altering expression of key regulators by repression of epithelial markers and upregulation of mesenchymal proteins (70). At present, the mechanism by which EMT was initiated in thyroid tumor cells of ThrbPV/PV mice is not clearly understood. However, secreted TGFβ1 in the serum was higher as early as age 3 months and persistently higher at 5 months in ThrbPV/PV mice than in WT mice (Figure 3C). This finding together with a concomitant elevated expression of TGFβRII suggests that one of the early events leading to EMT could be driven by elevated TGFβ1 activity. This notion is consistent with the gene expression profile-based network analysis discussed above (also see Figure 2A and Table 1). However, it is important to point out that we have shown previously that PV-activated Src–focal adhesion kinase signaling could work independently and/or in collaboration with activated TGFβ signaling, driving EMT to increase cell invasion and metastasis in thyroid carcinogenesis of ThrbPV/PV mice.

It is well recognized that during thyroid carcinogenesis, there are ongoing genetic molecular changes from the initiating events in primary lesions to distant metastasis and from differentiated tumors to undifferentiated cancer. However, detailed systematic analysis of gene expression profiles undergoing temporal changes during carcinogenesis would not be possible in patients for ethical and practical reasons. Using ThrbPV/PV mice the present studies provided evidence to indicate that thyroid carcinogenesis is driven by complex progressive changes in the expression of many genes with defined patterns. Therefore, after the initiating events, temporal interconnected alterations in gene expression direct the tumor cells on the paths toward metastasis and toward loss of differentiation. Efforts have long been directed toward identifying prognostic factors to better define the disease state and to predict the possible outcome. The importance of signature-recognizable patterns of multiple genes could be considered to be far more reliable prognostic indicators than sole reliance on a single gene. Our study was the first of this kind of gene expression analysis from a mouse model with pathological progression similar to human FTC. Thus, the temporal gene expression patterns we uncovered could be considered for use as potential prognostic signatures. Moreover, on the basis of recognizable expression of multiple genes at a certain disease state, a better choice of effective treatment modality could be achieved by targeting the affected aberrant pathways.

Supplementary material

Supplementary Table A can be found at http://carcin.oxfordjournals.org/

Funding

Intramural Research Program at the Center for Cancer Research, National Cancer Institute, National Institutes of Health.

Acknowledgement

We thank Dr Fumihiko Furuya for the contributions in early phase of this present work.

Conflict of Interest Statement: None declared.

References


38. Norris,A. et al. (2011) LMO7 is a SMAD4-suppressible gene that modulates MUC1 levels and promotes the initiation and progression of pancreatic intraepithelial neoplasia. Oncogene. http://dx.doi.org/10.1038/onc.2012.394 (3 September 2012, date last accessed).


Received December 13, 2012; revised April 12, 2013; accepted May 18, 2013